Latest Biotech Startup Funding Rounds

Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.

This page showsSector: Biotech
Rounds
153
Jul 18 – Oct 15, 2026
Disclosed funding
$5.2B
123 disclosed amounts
Median round
$20M
Of disclosed amounts
153 rounds
Funding rounds
CompanyAmountRoundSectorCountryInvestorsAnnounced
Tempo TherapeuticsBiotech · United StatesCompany profile

A regenerative-medicine company developing injectable microporous scaffolds that help the body rebuild tissue at damaged sites.

A regenerative-medicine company developing injectable microporous scaffolds that help the body rebuild tissue at damaged sites.

≤$2.3MNCI SBIR grantUndisclosedBiotechUnited StatesInvestors
Basecamp ResearchBiotech · United KingdomCompany profile

Basecamp Research builds biological AI models from genomic data to help design therapeutics, including protein-based medicines.

Basecamp Research builds biological AI models from genomic data to help design therapeutics, including protein-based medicines.

$140MSeries CSeries C+BiotechUnited KingdomInvestors
EnvedaBiotech · United StatesCompany profile

Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases.

Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases.

$311MSeries ESeries C+BiotechUnited StatesInvestors
Azulene LabsBiotech · —Company profile

Physics-informed AI predicts molecular properties and chemical behavior for drug and materials research.

Physics-informed AI predicts molecular properties and chemical behavior for drug and materials research.

$3.4MPre-SeedPre-seedBiotech—Investors
Primrose BioBiotech · United StatesCompany profile

Primrose Bio supplies manufacturing technologies for biologic drugs, mRNA products and vaccines.

Primrose Bio supplies manufacturing technologies for biologic drugs, mRNA products and vaccines.

UndisclosedGrowth financingGrowthBiotechUnited StatesInvestors
CellsBinBiotech · United StatesCompany profile

A biotechnology company developing rare-cell detection and single-cell analysis tools for cancer monitoring.

A biotechnology company developing rare-cell detection and single-cell analysis tools for cancer monitoring.

UndisclosedSeries ABiotechUnited StatesInvestors
Molecular Targeting Technologies, Inc.Biotech · United StatesCompany profile

A clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer treatment and diagnosis.

A clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer treatment and diagnosis.

$3.2MNational Cancer Institute R01 grantUndisclosedBiotechUnited StatesInvestors
ImpriMedHealthtech · South KoreaCompany profile

A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient.

A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient.

$10MSeries A2 bridgeUndisclosedBiotech, HealthtechSouth KoreaInvestors
Axio BioPharmaEnterprise software · United StatesCompany profile

A data platform that connects pharmaceutical manufacturers and their production partners while each organization keeps control of its own systems and records.

A data platform that connects pharmaceutical manufacturers and their production partners while each organization keeps control of its own systems and records.

$2.4MPre-seedBiotech, Enterprise softwareUnited StatesInvestors
Novadip BiosciencesBiotech · BelgiumCompany profile

A clinical-stage biotechnology company developing regenerative cell therapies and grafts to repair bone and other damaged tissues, including a pivotal-stage treatment for a rare pediatric bone disorder.

A clinical-stage biotechnology company developing regenerative cell therapies and grafts to repair bone and other damaged tissues, including a pivotal-stage treatment for a rare pediatric bone disorder.

€10.4MConvertible financingUndisclosedBiotechBelgiumInvestors

Active investors in this selection

All investors →

Ranked by rounds participated in · From Jul 18, 2026

  1. 1
    Eli Lilly and Company

    BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences

    10rounds
    0led
  2. 2
    RA Capital Management

    Circle Pharma, Inc., Solstice Oncology, Superluminal Medicines

    8rounds
    2led
  3. 3
    Y Combinator (YC)

    Molagri, Sensible Biotechnologies, WonderTx

    6rounds
    0led
  4. 4
    Catalio Capital Management

    BigHat Biosciences, Basecamp Research, Enveda

    6rounds
    2led
  5. 5
    Oxford Science Enterprises

    OMass Therapeutics, ReEmerge, Inc., Vivid Dx

    5rounds
    0led

Latest digests

Archive →

Explore published rounds while the next edition is being prepared.

Browse rounds by topic